NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
study, MAGNITUDE-2, evaluating nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). NTLA shares gained nearly 6.3% on Tuesday following the regulatory update. Over the past year, Intellia Therapeutics' shares have surged 46.6% compared with the industry's 17.2% rise. Image Source: Zacks Investment Research In October 2025, Intellia halted dosing and patient enrollment in its late-stage MAGNITUDE and MAGNITUDE-2 studies, which were evaluating nex-z for ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTRv-PN, respectively. The studies were halted after a patient experienced grade 4 liver transaminase elevations and increased total bilirubin following dosing with nex-Z and later died. This triggered a clinical hold by the FDA on the IND and raised widespread concerns about the safety and future of the program. Intellia has aligned with the FDA on specific study modifications and risk-mitigation measures for M
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics (NASDAQ:NTLA) was given a new $25.00 price target on by analysts at KeyCorp.MarketBeat
- Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? [Yahoo! Finance]Yahoo! Finance
- Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and MedicineGlobeNewswire
- Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Intellia Therapeutics (NASDAQ:NTLA) was given a new $7.00 price target on by analysts at Robert W. Baird.MarketBeat
NTLA
Earnings
- 11/6/25 - Beat
NTLA
Sec Filings
- 1/30/26 - Form SCHEDULE
- 1/27/26 - Form 8-K
- 1/9/26 - Form 8-K
- NTLA's page on the SEC website